Navigation Links
Vasogen Announces First Quarter 2008 Results

MISSISSAUGA, ON, April 3 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN; TSX:VAS), today reported the results of operations for the three months ended February 29, 2008. All dollar amounts referenced herein are in Canadian dollars unless otherwise noted.

At February 29, 2008, our cash and cash equivalents totaled $19.9 million, compared with $23.5 million at November 30, 2007.

We incurred a net loss for the three months ended February 29, 2008, of $5.3 million, or $0.24 per common share, compared with a net loss of $7.7 million, or $0.47 per common share for the same period in 2007. A key driver of this decrease was a $1.6 million reduction in expenses resulting from the repayment of the senior convertible notes in April 2007, and lower infrastructure and other support costs driven by lower employee numbers in 2008.

For the three months ended February 29, 2008, research and development expenses decreased to $2.8 million from $3.0 million for the comparable period in 2007. During the first quarter of 2008, these costs were incurred for the initial commercialization of Celacade in Europe and for preparations for ACCLAIM II, a study designed to evaluate the Celacade technology for the treatment of patients with NYHA Class II heart failure.

General and administration expenses were $2.7 million for the three months ended February 29, 2008, compared to $3.6 million for the same period in 2007 as a result of lower employee numbers.


- In January, preclinical findings demonstrating that VP025, the lead

candidate from our VP series of drugs, provides a significant

neuroprotective effect in a model of Parkinson's disease were

published in the European Jou - (35)

Change in non-cash operating

working capital 1,398 (3,475) 2,349


(3,433) (9,016) (328,195)

Financing activities:

Shares and warrants issued for cash - - 326,358

Warrants exercised for cash - - 16,941

Options exercised for cash - - 7,669

Share issue costs - 3 (24,646)

Issue (repayment) of senior

convertible notes payable, net - (635) 38,512

Cash released from restriction - 3,036 -

Paid to related parties - - (234)


- 2,404 364,600

Investing activities:

Purchases of property and equipment - (30) (2,465)

Purchases of acquired technology - - (1,283)

Purchases of marketable securities - - (244,846)

Settlement of forward foreign

exchange contracts - 10 (4,824)

Maturities of marketable securities - - 240,677


- (20) (12,741)

Foreign exchange gain (loss) on cash

held in foreign currency (182) 280 (3,734)


Increase (decrease) in cash and cash

equivalents (3,615) (6,352) 19,930

Cash and cash equivalents, beginning

of period 23,545 30,427 -


Cash and cash equivalents, end of

period $ 19,930 $ 24,075 $ 19,930



rnal of Neuroscience (Vol 27, pp.294-

300, 2008).

- The results from the phase III ACCLAIM trial of our Celacade System

in patients with chronic heart failure were published in the

January 19th issue of The Lancet (Lancet 2008; 371: 228-36), a world-

leading medical journal. As we previously reported, while the trial

did not meet its primary endpoint, a key finding from the ACCLAIM

trial was a 39% reduction in the risk of death or cardiovascular

hospitalizations for a large pre-specified subgroup of patients with

NYHA Class II heart failure who received Celacade therapy, compared

to patients receiving placebo.

- On March 14, 2008, we had a teleconference with the FDA to discuss

and clarify the recent comments from the agency regarding the use of

a Bayesian approach for ACCLAIM II, a clinical trial which is being

planned to support an application for U.S. market approval of the

Celacade System for the treatment of patients with New York Heart

Association ("NYHA") Class II heart failure. The teleconference with

the FDA follows our announcement on March 3rd, stating that the FDA

disagrees with the use of a Bayesian approach for the planned ACCLAIM

II study. This is contrary to the FDA's original communication to us

recommending a Bayesian study design. We have prepared and submitted

a written response to the FDA's comments with respect to the use of a

Bayesian approach in ACCLAIM II.

- Grupo Ferrer Internacional, S.A. ("Ferrer"), our European marketing

partner, has the right to market Celacade for the treatment of

chronic heart failure in certain countries of the European Union

("E.U.") and Latin America. Celacade has already received E.U.

regulatory approval as a medical device under the CE Mark, which

enables marketing of Celacade for the treatment of chronic heart

failure in the 27 member countries of the E.U. Celacade is also the

only CE Mark approved product that specifically targets the

destructive chronic inflammation underlying the development and

progression of heart failure. Under the CE Mark in Europe, Celacade

is approved for the treatment of all NYHA Class II patients and NYHA

Class III, & IV heart failure patients who do not have a history of

prior heart attack. We currently expect that the first clinical sites

in Germany will be in a position to offer Celacade therapy to

patients in April 2008.

Due to the fact that we recently provided a detailed update on corporate activities during our Annual Shareholders' Meeting on March 25, 2008, we will not host a conference call at this time. A replay of the Annual Shareholders' Meeting presentation is available at

About Vasogen:

Vasogen is a biotechnology company engaged in the research and commercial development of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. The Company's lead product, the Celacade(TM) System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is being marketed in the EU by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage clinical development for the treatment of chronic heart failure in the United States. Vasogen is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead candidate from this new class of drugs.

Certain statements contained in this press release, or elsewhere in our public documents constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or "forward-looking information" under the Securities Act (Ontario). These statements may include, without limitation, plans to advance the development of the Celacade(TM) System or VP025, plans to fund our current activities, statements concerning our partnering activities, health regulatory submissions, strategy, future operations, future financial position, future revenues and projected costs. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expects", "plans", "anticipates", "believes", "estimated", "predicts", "potential", "continue", "intends", "could", or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of these forward-looking statements, including assumptions about the nature, size, and accessibility of the market for Celacade in the treatment of chronic heart failure, particularly in Europe, the regulatory approval process leading to commercialization and the availability of capital on acceptable terms to pursue the development of Celacade, and the feasibility of additional trials. You should not place undue reliance on our forward-looking statements which are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those projected. These risks include, but are not limited to, the outcome of further ongoing analysis of the ACCLAIM trial results, the requirement or election to conduct additional clinical trials and the size and design of any such trials, delays or setbacks in the regulatory approval process, difficulties in the maintenance of existing regulatory approvals, securing and maintaining corporate alliances, the need for additional capital and the effect of capital market conditions and other factors on capital availability, the potential dilutive effects of any financing, risks associated with the outcomes of our preclinical and clinical research and development programs, the adequacy, timing, and results of our clinical trials, competition, market acceptance of our products, the availability of government and insurance reimbursements for our products, the strength of intellectual property, reliance on partners, subcontractors, and key personnel, losses due to fluctuations in the U.S.-Canadian exchange rate, and other risks detailed from time to time in our public disclosure documents or other filings with the Canadian and U.S. securities commissions or other securities regulatory bodies. Additional risks and uncertainties relating to our Company and our business can be found in the "Risk Factors" section of our Annual Information Form and Form 20-F for the year ended November 30, 2007, as well as in our later public filings. The forward-looking statements are made as of the date hereof, and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

The unaudited interim consolidated financial statements, accompanying notes to the unaudited interim consolidated financial statements, and Management's Discussion and Analysis for the three months ended February 29, 2008, will be accessible on Vasogen's Website at and will be available on SEDAR and EDGAR.

Summary financial tables are provided below.



Interim Consolidated Balance Sheets

(In thousands of Canadian dollars)


February 29, November 30,

2008 2007




Current assets:

Cash and cash equivalents $ 19,930 $ 23,545

Clinical supplies 1,270 1,363

Tax credits recoverable 738 1,565

Prepaid expenses and deposits 600 787

Change in fair value of forward foreign

exchange contracts - 376


22,538 27,636

Property and equipment 352 414


$ 22,890 $ 28,050



Liabilities and Shareholders' Equity

Current liabilities:

Accounts payable $ 1,190 $ 1,175

Accrued liabilities 3,429 3,519


4,619 4,694

Shareholders' equity

Share capital:


Unlimited common shares, without par value

Issued and outstanding:

22,391,386 common shares

(November 30, 2007 - 22,391,386) 365,670 365,670

Warrants 16,725 16,725

Contributed surplus 22,979 22,744

Deficit (387,103) (381,783)


18,271 23,356

Future operations

Commitments and contingencies

Subsequent events


$ 22,890 $ 28,050





Interim Consolidated Statements of Operations, Deficit and Comprehensive


(In thousands of Canadian dollars, except per share amounts)



Period from

December 1,

Three months ended 1987 to

February 29, February 28, February 29,

2008 2007 2008



Research and development $ 2,778 $ 3,023 $ 241,695

General and administration 2,681 3,588 119,909

Foreign exchange loss (gain) 203 (134) 11,173


Loss before the undernoted (5,662) (6,477) (372,777)

Interest expense on senior

convertible notes payable - (5) (1,279)

Accretion in carrying value of

senior convertible notes payable - (692) (10,294)

Amortization of deferred financing

costs - (145) (3,057)

Loss on extinguishment of senior

convertible notes payable - (1,284) (6,749)

Investment income 342 352 13,667

Change in fair value of embedded

derivatives - 573 829


Loss and comprehensive loss for

the period (5,320) (7,678) (379,660)

Deficit, beginning of period:

As originally reported (381,783) (351,374) (1,510)

Impact of change in accounting

for stock-based compensation - - (4,006)

Impact of change in accounting

for financial instruments on

December 1, 2006 - (1,632) (1,632)


As revised (381,783) (353,006)

Charge for acceleration payments

on equity component of senior

convertible notes payable - - (295)


Deficit, end of period $ (387,103) $ (360,684) $ (387,103)



Basic and diluted loss per common

share $ (0.24) $ (0.47) $ -





Interim Consolidated Statements of Cash Flows

(In thousands of Canadian dollars)



Period from

December 1,

Three months ended 1987 to

February 29, February 28, February 29,

2008 2007 2008


Cash provided by (used in):

Operating activities:

Loss for the period $ (5,320) $ (7,678) $ (379,660)

Items not involving cash:

Amortization 62 126 6,222

Accretion in carrying value of

senior convertible notes payable - 692 10,294

Amortization of deferred

financing costs - 145 3,057

Loss on extinguishment of

senior convertible notes payable - 1,284 6,749

Change in fair value of

embedded derivatives - (573) (829)

Stock-based compensation 235 563 9,814

Common shares issued for services - - 2,485

Unrealized gain on forward

foreign exchange contract - - (376)

Unrealized foreign exchange

loss (gain) 192 (100) 11,735

Other -

SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
11. Vasogen Provides Update on ACCLAIM II Program
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... ... Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief research ... Inc. has been selected for membership in ARCS Alumni Hall of Fame ...
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia Inc ... hosting a Webinar titled, “Pathology is going digital. Is your lab ready?” with ... adoption best practices and how Proscia improves lab economics and realizes an increase ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... implantation and pregnancy rates in frozen and fresh in vitro fertilization (IVF) ... and maternal age to IVF success. , After comparing the results from the ...
(Date:10/10/2017)... Philadelphia, PA (PRWEB) , ... October 10, 2017 ... ... University City Science Center’s FirstHand program has won a US2020 STEM Mentoring Award. ... accept the award for Excellence in Volunteer Experience from US2020. , US2020’s mission ...
Breaking Biology Technology:
(Date:4/19/2017)... ALBANY, New York , April 19, 2017 /PRNewswire/ ... highly competitive, as its vendor landscape is marked by ... in the market is however held by five major ... and Safran. Together these companies accounted for nearly 61% ... majority of the leading companies in the global military ...
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... , April 11, 2017 NXT-ID, Inc. ... technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate governance ... Gino ... we look forward to their guidance and benefiting from their ...
Breaking Biology News(10 mins):